BHC (Bausch Health) Stock Based Compensation: $225 Mil (TTM As of Mar. 2026)


BHC Bausch Health Companies Inc BHC
58 GF Score
Price $4.90
GF Value $7.56
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Bausch Health Stock Based Compensation?

Bausch Health BHC +2.73% 58 Stock Based Compensation is $225 Mil as of Mar. 2026. GuruFocus rates BHC with a GF Score™ of 58/100 and a GF Value™ of $7.56 (Possible Value Trap). The stock has 3 warning signs investors should review.

Bausch Health's Stock Based Compensation for the three months ended in Mar. 2026 was $52 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was $225 Mil.

Bausch Health Stock Based Compensation Related Terms

Bausch Health Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Bausch Health's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bausch Health Stock Based Compensation Chart

Bausch Health Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 128.00 126.00 132.00 150.00 216.00

Bausch Health Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 43.00 46.00 43.00 84.00 52.00
BHC
58GF Score
Bausch Health Companies Inc BHC
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bausch Health Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $225 Mil.

What does a Stock Based Compensation of $225 Mil mean?
Bausch Health (BHC) has a Stock Based Compensation of $225 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Bausch Health and its competitors.
Is Bausch Health's Stock Based Compensation too high?
Bausch Health's current Stock Based Compensation is $225 Mil. Overall, Bausch Health has a GF Score™ of 58/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Bausch Health's Stock Based Compensation compare to ZTS and UTHR?
Bausch Health's Stock Based Compensation of $225 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Drug Manufacturers company?
A good Stock Based Compensation depends on the Drug Manufacturers industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Bausch Health and its competitors. Bausch Health's current Stock Based Compensation is $225 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bausch Health stock overvalued right now?
Based on GuruFocus' analysis, Bausch Health (BHC) is currently considered Possible Value Trap. The stock's GF Value™ is $7.56, compared to a current price of $4.90 — trading 35.2% below its estimated fair value. The current Stock Based Compensation is $225 Mil. Bausch Health's overall GF Score™ is 58/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Bausch Health (BHC), the current Stock Based Compensation is $225 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bausch Health (BHC) Overvalued in 2026?

Based on GuruFocus' analysis, Bausch Health stock appears to be undervalued. The current stock price of $4.90 is trading 35.2% below its estimated GF Value™ of $7.56. GuruFocus considers Bausch Health to be Possible Value Trap.

Key valuation signals for BHC:

  • Stock Based Compensation: $225 Mil
  • GF Value™: $7.56 vs. price of $4.90 (35.2% below fair value)
  • GF Score™: 58/100 with 3 warning signs

No single metric tells the full story. See the BHC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bausch Health Business Description

Address 2150 St Elzear Boulvard West, Laval, QC, CAN, H7L 4A8
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum of its revenue from the Bausch + Lomb segment.
58GF Score

Get the complete analysis for BHC

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.90
Price
$7.56
GF Value